Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Traws Pharma (TRAW) over the last 13 years, with Q3 2025 value amounting to $3000.0.

  • Traws Pharma's Gains from Investment Securities changed N/A to $3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year change of. This contributed to the annual value of $24.4 million for FY2024, which is 2633632.15% up from last year.
  • As of Q3 2025, Traws Pharma's Gains from Investment Securities stood at $3000.0.
  • In the past 5 years, Traws Pharma's Gains from Investment Securities ranged from a high of $24.4 million in Q4 2024 and a low of -$26.5 million during Q1 2025
  • Moreover, its 4-year median value for Gains from Investment Securities was -$77500.0 (2022), whereas its average is -$318500.0.
  • Data for Traws Pharma's Gains from Investment Securities shows a peak YoY increase of 90952.38% (in 2021) and a maximum YoY decrease of 86250.0% (in 2021) over the last 5 years.
  • Over the past 4 years, Traws Pharma's Gains from Investment Securities (Quarter) stood at -$530000.0 in 2021, then surged by 98.3% to -$9000.0 in 2022, then skyrocketed by 271633.33% to $24.4 million in 2024, then plummeted by 99.99% to $3000.0 in 2025.
  • Its Gains from Investment Securities was $3000.0 in Q3 2025, compared to -$146000.0 in Q2 2025 and -$26.5 million in Q1 2025.